<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.analytics.v2.soap.AnalyticsOutputV2 xmlns:ns2="local" rowCount="112"><Row><Indication id="20">Pain</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>2</StatusSortCode><Action id="2946">Analgesic</Action><Company id="1006865">Nascime Ltd</Company><Country id="WO">World</Country><Drug id="39897">bicifadine (sustained-release, pain), DOV</Drug><ParentCompany id="1052448">Euthymics Bioscience Inc</ParentCompany><Status id="PUB">First Publication</Status><TherapyArea id="677">Neurological disease</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship>Product</DrugRelationship><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Patent id="PA2888121">WO-2004012722</Patent></Row><Row><Indication id="20">Pain</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>2</StatusSortCode><Action id="2946">Analgesic</Action><Company id="22124">XTL Biopharmaceuticals Ltd</Company><Country id="WO">World</Country><Drug id="39897">bicifadine (sustained-release, pain), DOV</Drug><ParentCompany id="22124">XTL Biopharmaceuticals Ltd</ParentCompany><Status id="PUB">First Publication</Status><TherapyArea id="677">Neurological disease</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship>Product</DrugRelationship><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Patent id="PA2888121">WO-2004012722</Patent></Row><Row><Indication id="20">Pain</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>1</StatusSortCode><Action id="2946">Analgesic</Action><Company id="1006865">Nascime Ltd</Company><Country id="US">US</Country><Drug id="39897">bicifadine (sustained-release, pain), DOV</Drug><ParentCompany id="1052448">Euthymics Bioscience Inc</ParentCompany><Status id="PRI">First Priority</Status><TherapyArea id="677">Neurological disease</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship>Product</DrugRelationship><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Patent id="PA2888121">WO-2004012722</Patent></Row><Row><Indication id="20">Pain</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>1</StatusSortCode><Action id="2946">Analgesic</Action><Company id="22124">XTL Biopharmaceuticals Ltd</Company><Country id="US">US</Country><Drug id="39897">bicifadine (sustained-release, pain), DOV</Drug><ParentCompany id="22124">XTL Biopharmaceuticals Ltd</ParentCompany><Status id="PRI">First Priority</Status><TherapyArea id="677">Neurological disease</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship>Product</DrugRelationship><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Patent id="PA2888121">WO-2004012722</Patent></Row><Row><Indication id="20">Pain</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>2</StatusSortCode><Action id="2946">Analgesic</Action><Company id="1052448">Euthymics Bioscience Inc</Company><Country id="WO">World</Country><Drug id="39897">bicifadine (sustained-release, pain), DOV</Drug><ParentCompany id="1052448">Euthymics Bioscience Inc</ParentCompany><Status id="PUB">First Publication</Status><TherapyArea id="677">Neurological disease</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship>Product (derivative)</DrugRelationship><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Patent id="PA2897870">WO-2004043920</Patent></Row><Row><Indication id="20">Pain</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>2</StatusSortCode><Action id="2946">Analgesic</Action><Company id="1052448">Euthymics Bioscience Inc</Company><Country id="WO">World</Country><Drug id="39897">Bicifadine</Drug><ParentCompany id="1052448">Euthymics Bioscience Inc</ParentCompany><Status id="PUB">First Publication</Status><TherapyArea id="677">Neurological disease</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship>Product (derivative)</DrugRelationship><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Patent id="PA2897870">WO-2004043920</Patent></Row><Row><Indication id="20">Pain</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>1</StatusSortCode><Action id="2946">Analgesic</Action><Company id="1052448">Euthymics Bioscience Inc</Company><Country id="US">US</Country><Drug id="39897">bicifadine (sustained-release, pain), DOV</Drug><ParentCompany id="1052448">Euthymics Bioscience Inc</ParentCompany><Status id="PRI">First Priority</Status><TherapyArea id="677">Neurological disease</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship>Product (derivative)</DrugRelationship><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Patent id="PA2897870">WO-2004043920</Patent></Row><Row><Indication id="20">Pain</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>1</StatusSortCode><Action id="2946">Analgesic</Action><Company id="1052448">Euthymics Bioscience Inc</Company><Country id="US">US</Country><Drug id="39897">Bicifadine</Drug><ParentCompany id="1052448">Euthymics Bioscience Inc</ParentCompany><Status id="PRI">First Priority</Status><TherapyArea id="677">Neurological disease</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship>Product (derivative)</DrugRelationship><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Patent id="PA2897870">WO-2004043920</Patent></Row><Row><Indication id="1241">Prostate hyperplasia</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>2</StatusSortCode><Action id="281">NMDA receptor antagonist</Action><Company id="30151">Dynogen Pharmaceuticals Inc</Company><Country id="WO">World</Country><Drug id="39897">Bicifadine</Drug><ParentCompany id="30151">Dynogen Pharmaceuticals Inc</ParentCompany><Status id="PUB">First Publication</Status><TherapyArea id="140">Growth disorder</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship>New use</DrugRelationship><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Patent id="PA3068301">WO-2005117872</Patent></Row><Row><Indication id="187">Urinary incontinence</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>2</StatusSortCode><Action id="281">NMDA receptor antagonist</Action><Company id="30151">Dynogen Pharmaceuticals Inc</Company><Country id="WO">World</Country><Drug id="39897">Bicifadine</Drug><ParentCompany id="30151">Dynogen Pharmaceuticals Inc</ParentCompany><Status id="PUB">First Publication</Status><TherapyArea id="366">Genitourinary disease</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship>New use</DrugRelationship><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Patent id="PA3068301">WO-2005117872</Patent></Row><Row><Indication id="366">Genitourinary disease</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>2</StatusSortCode><Action id="281">NMDA receptor antagonist</Action><Company id="30151">Dynogen Pharmaceuticals Inc</Company><Country id="WO">World</Country><Drug id="39897">Bicifadine</Drug><ParentCompany id="30151">Dynogen Pharmaceuticals Inc</ParentCompany><Status id="PUB">First Publication</Status><TherapyArea id="366">Genitourinary disease</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship>New use</DrugRelationship><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Patent id="PA3068301">WO-2005117872</Patent></Row><Row><Indication id="483">Urinary dysfunction</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>2</StatusSortCode><Action id="281">NMDA receptor antagonist</Action><Company id="30151">Dynogen Pharmaceuticals Inc</Company><Country id="WO">World</Country><Drug id="39897">Bicifadine</Drug><ParentCompany id="30151">Dynogen Pharmaceuticals Inc</ParentCompany><Status id="PUB">First Publication</Status><TherapyArea id="366">Genitourinary disease</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship>New use</DrugRelationship><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Patent id="PA3068301">WO-2005117872</Patent></Row><Row><Indication id="486">Bladder disease</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>2</StatusSortCode><Action id="281">NMDA receptor antagonist</Action><Company id="30151">Dynogen Pharmaceuticals Inc</Company><Country id="WO">World</Country><Drug id="39897">Bicifadine</Drug><ParentCompany id="30151">Dynogen Pharmaceuticals Inc</ParentCompany><Status id="PUB">First Publication</Status><TherapyArea id="366">Genitourinary disease</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship>New use</DrugRelationship><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Patent id="PA3068301">WO-2005117872</Patent></Row><Row><Indication id="1241">Prostate hyperplasia</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>2</StatusSortCode><Action id="285">Norepinephrine uptake inhibitor</Action><Company id="30151">Dynogen Pharmaceuticals Inc</Company><Country id="WO">World</Country><Drug id="39897">Bicifadine</Drug><ParentCompany id="30151">Dynogen Pharmaceuticals Inc</ParentCompany><Status id="PUB">First Publication</Status><TherapyArea id="140">Growth disorder</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship>New use</DrugRelationship><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Patent id="PA3068301">WO-2005117872</Patent></Row><Row><Indication id="187">Urinary incontinence</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>2</StatusSortCode><Action id="285">Norepinephrine uptake inhibitor</Action><Company id="30151">Dynogen Pharmaceuticals Inc</Company><Country id="WO">World</Country><Drug id="39897">Bicifadine</Drug><ParentCompany id="30151">Dynogen Pharmaceuticals Inc</ParentCompany><Status id="PUB">First Publication</Status><TherapyArea id="366">Genitourinary disease</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship>New use</DrugRelationship><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Patent id="PA3068301">WO-2005117872</Patent></Row><Row><Indication id="366">Genitourinary disease</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>2</StatusSortCode><Action id="285">Norepinephrine uptake inhibitor</Action><Company id="30151">Dynogen Pharmaceuticals Inc</Company><Country id="WO">World</Country><Drug id="39897">Bicifadine</Drug><ParentCompany id="30151">Dynogen Pharmaceuticals Inc</ParentCompany><Status id="PUB">First Publication</Status><TherapyArea id="366">Genitourinary disease</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship>New use</DrugRelationship><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Patent id="PA3068301">WO-2005117872</Patent></Row><Row><Indication id="483">Urinary dysfunction</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>2</StatusSortCode><Action id="285">Norepinephrine uptake inhibitor</Action><Company id="30151">Dynogen Pharmaceuticals Inc</Company><Country id="WO">World</Country><Drug id="39897">Bicifadine</Drug><ParentCompany id="30151">Dynogen Pharmaceuticals Inc</ParentCompany><Status id="PUB">First Publication</Status><TherapyArea id="366">Genitourinary disease</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship>New use</DrugRelationship><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Patent id="PA3068301">WO-2005117872</Patent></Row><Row><Indication id="486">Bladder disease</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>2</StatusSortCode><Action id="285">Norepinephrine uptake inhibitor</Action><Company id="30151">Dynogen Pharmaceuticals Inc</Company><Country id="WO">World</Country><Drug id="39897">Bicifadine</Drug><ParentCompany id="30151">Dynogen Pharmaceuticals Inc</ParentCompany><Status id="PUB">First Publication</Status><TherapyArea id="366">Genitourinary disease</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship>New use</DrugRelationship><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Patent id="PA3068301">WO-2005117872</Patent></Row><Row><Indication id="1241">Prostate hyperplasia</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>2</StatusSortCode><Action id="7293">Synergist</Action><Company id="30151">Dynogen Pharmaceuticals Inc</Company><Country id="WO">World</Country><Drug id="39897">Bicifadine</Drug><ParentCompany id="30151">Dynogen Pharmaceuticals Inc</ParentCompany><Status id="PUB">First Publication</Status><TherapyArea id="140">Growth disorder</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship>New use</DrugRelationship><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Patent id="PA3068301">WO-2005117872</Patent></Row><Row><Indication id="187">Urinary incontinence</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>2</StatusSortCode><Action id="7293">Synergist</Action><Company id="30151">Dynogen Pharmaceuticals Inc</Company><Country id="WO">World</Country><Drug id="39897">Bicifadine</Drug><ParentCompany id="30151">Dynogen Pharmaceuticals Inc</ParentCompany><Status id="PUB">First Publication</Status><TherapyArea id="366">Genitourinary disease</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship>New use</DrugRelationship><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Patent id="PA3068301">WO-2005117872</Patent></Row><Row><Indication id="366">Genitourinary disease</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>2</StatusSortCode><Action id="7293">Synergist</Action><Company id="30151">Dynogen Pharmaceuticals Inc</Company><Country id="WO">World</Country><Drug id="39897">Bicifadine</Drug><ParentCompany id="30151">Dynogen Pharmaceuticals Inc</ParentCompany><Status id="PUB">First Publication</Status><TherapyArea id="366">Genitourinary disease</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship>New use</DrugRelationship><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Patent id="PA3068301">WO-2005117872</Patent></Row><Row><Indication id="483">Urinary dysfunction</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>2</StatusSortCode><Action id="7293">Synergist</Action><Company id="30151">Dynogen Pharmaceuticals Inc</Company><Country id="WO">World</Country><Drug id="39897">Bicifadine</Drug><ParentCompany id="30151">Dynogen Pharmaceuticals Inc</ParentCompany><Status id="PUB">First Publication</Status><TherapyArea id="366">Genitourinary disease</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship>New use</DrugRelationship><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Patent id="PA3068301">WO-2005117872</Patent></Row><Row><Indication id="486">Bladder disease</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>2</StatusSortCode><Action id="7293">Synergist</Action><Company id="30151">Dynogen Pharmaceuticals Inc</Company><Country id="WO">World</Country><Drug id="39897">Bicifadine</Drug><ParentCompany id="30151">Dynogen Pharmaceuticals Inc</ParentCompany><Status id="PUB">First Publication</Status><TherapyArea id="366">Genitourinary disease</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship>New use</DrugRelationship><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Patent id="PA3068301">WO-2005117872</Patent></Row><Row><Indication id="1241">Prostate hyperplasia</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>1</StatusSortCode><Action id="281">NMDA receptor antagonist</Action><Company id="30151">Dynogen Pharmaceuticals Inc</Company><Country id="US">US</Country><Drug id="39897">Bicifadine</Drug><ParentCompany id="30151">Dynogen Pharmaceuticals Inc</ParentCompany><Status id="PRI">First Priority</Status><TherapyArea id="140">Growth disorder</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship>New use</DrugRelationship><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Patent id="PA3068301">WO-2005117872</Patent></Row><Row><Indication id="187">Urinary incontinence</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>1</StatusSortCode><Action id="281">NMDA receptor antagonist</Action><Company id="30151">Dynogen Pharmaceuticals Inc</Company><Country id="US">US</Country><Drug id="39897">Bicifadine</Drug><ParentCompany id="30151">Dynogen Pharmaceuticals Inc</ParentCompany><Status id="PRI">First Priority</Status><TherapyArea id="366">Genitourinary disease</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship>New use</DrugRelationship><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Patent id="PA3068301">WO-2005117872</Patent></Row><Row><Indication id="366">Genitourinary disease</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>1</StatusSortCode><Action id="281">NMDA receptor antagonist</Action><Company id="30151">Dynogen Pharmaceuticals Inc</Company><Country id="US">US</Country><Drug id="39897">Bicifadine</Drug><ParentCompany id="30151">Dynogen Pharmaceuticals Inc</ParentCompany><Status id="PRI">First Priority</Status><TherapyArea id="366">Genitourinary disease</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship>New use</DrugRelationship><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Patent id="PA3068301">WO-2005117872</Patent></Row><Row><Indication id="483">Urinary dysfunction</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>1</StatusSortCode><Action id="281">NMDA receptor antagonist</Action><Company id="30151">Dynogen Pharmaceuticals Inc</Company><Country id="US">US</Country><Drug id="39897">Bicifadine</Drug><ParentCompany id="30151">Dynogen Pharmaceuticals Inc</ParentCompany><Status id="PRI">First Priority</Status><TherapyArea id="366">Genitourinary disease</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship>New use</DrugRelationship><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Patent id="PA3068301">WO-2005117872</Patent></Row><Row><Indication id="486">Bladder disease</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>1</StatusSortCode><Action id="281">NMDA receptor antagonist</Action><Company id="30151">Dynogen Pharmaceuticals Inc</Company><Country id="US">US</Country><Drug id="39897">Bicifadine</Drug><ParentCompany id="30151">Dynogen Pharmaceuticals Inc</ParentCompany><Status id="PRI">First Priority</Status><TherapyArea id="366">Genitourinary disease</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship>New use</DrugRelationship><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Patent id="PA3068301">WO-2005117872</Patent></Row><Row><Indication id="1241">Prostate hyperplasia</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>1</StatusSortCode><Action id="285">Norepinephrine uptake inhibitor</Action><Company id="30151">Dynogen Pharmaceuticals Inc</Company><Country id="US">US</Country><Drug id="39897">Bicifadine</Drug><ParentCompany id="30151">Dynogen Pharmaceuticals Inc</ParentCompany><Status id="PRI">First Priority</Status><TherapyArea id="140">Growth disorder</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship>New use</DrugRelationship><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Patent id="PA3068301">WO-2005117872</Patent></Row><Row><Indication id="187">Urinary incontinence</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>1</StatusSortCode><Action id="285">Norepinephrine uptake inhibitor</Action><Company id="30151">Dynogen Pharmaceuticals Inc</Company><Country id="US">US</Country><Drug id="39897">Bicifadine</Drug><ParentCompany id="30151">Dynogen Pharmaceuticals Inc</ParentCompany><Status id="PRI">First Priority</Status><TherapyArea id="366">Genitourinary disease</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship>New use</DrugRelationship><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Patent id="PA3068301">WO-2005117872</Patent></Row><Row><Indication id="366">Genitourinary disease</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>1</StatusSortCode><Action id="285">Norepinephrine uptake inhibitor</Action><Company id="30151">Dynogen Pharmaceuticals Inc</Company><Country id="US">US</Country><Drug id="39897">Bicifadine</Drug><ParentCompany id="30151">Dynogen Pharmaceuticals Inc</ParentCompany><Status id="PRI">First Priority</Status><TherapyArea id="366">Genitourinary disease</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship>New use</DrugRelationship><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Patent id="PA3068301">WO-2005117872</Patent></Row><Row><Indication id="483">Urinary dysfunction</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>1</StatusSortCode><Action id="285">Norepinephrine uptake inhibitor</Action><Company id="30151">Dynogen Pharmaceuticals Inc</Company><Country id="US">US</Country><Drug id="39897">Bicifadine</Drug><ParentCompany id="30151">Dynogen Pharmaceuticals Inc</ParentCompany><Status id="PRI">First Priority</Status><TherapyArea id="366">Genitourinary disease</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship>New use</DrugRelationship><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Patent id="PA3068301">WO-2005117872</Patent></Row><Row><Indication id="486">Bladder disease</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>1</StatusSortCode><Action id="285">Norepinephrine uptake inhibitor</Action><Company id="30151">Dynogen Pharmaceuticals Inc</Company><Country id="US">US</Country><Drug id="39897">Bicifadine</Drug><ParentCompany id="30151">Dynogen Pharmaceuticals Inc</ParentCompany><Status id="PRI">First Priority</Status><TherapyArea id="366">Genitourinary disease</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship>New use</DrugRelationship><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Patent id="PA3068301">WO-2005117872</Patent></Row><Row><Indication id="1241">Prostate hyperplasia</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>1</StatusSortCode><Action id="7293">Synergist</Action><Company id="30151">Dynogen Pharmaceuticals Inc</Company><Country id="US">US</Country><Drug id="39897">Bicifadine</Drug><ParentCompany id="30151">Dynogen Pharmaceuticals Inc</ParentCompany><Status id="PRI">First Priority</Status><TherapyArea id="140">Growth disorder</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship>New use</DrugRelationship><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Patent id="PA3068301">WO-2005117872</Patent></Row><Row><Indication id="187">Urinary incontinence</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>1</StatusSortCode><Action id="7293">Synergist</Action><Company id="30151">Dynogen Pharmaceuticals Inc</Company><Country id="US">US</Country><Drug id="39897">Bicifadine</Drug><ParentCompany id="30151">Dynogen Pharmaceuticals Inc</ParentCompany><Status id="PRI">First Priority</Status><TherapyArea id="366">Genitourinary disease</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship>New use</DrugRelationship><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Patent id="PA3068301">WO-2005117872</Patent></Row><Row><Indication id="366">Genitourinary disease</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>1</StatusSortCode><Action id="7293">Synergist</Action><Company id="30151">Dynogen Pharmaceuticals Inc</Company><Country id="US">US</Country><Drug id="39897">Bicifadine</Drug><ParentCompany id="30151">Dynogen Pharmaceuticals Inc</ParentCompany><Status id="PRI">First Priority</Status><TherapyArea id="366">Genitourinary disease</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship>New use</DrugRelationship><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Patent id="PA3068301">WO-2005117872</Patent></Row><Row><Indication id="483">Urinary dysfunction</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>1</StatusSortCode><Action id="7293">Synergist</Action><Company id="30151">Dynogen Pharmaceuticals Inc</Company><Country id="US">US</Country><Drug id="39897">Bicifadine</Drug><ParentCompany id="30151">Dynogen Pharmaceuticals Inc</ParentCompany><Status id="PRI">First Priority</Status><TherapyArea id="366">Genitourinary disease</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship>New use</DrugRelationship><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Patent id="PA3068301">WO-2005117872</Patent></Row><Row><Indication id="486">Bladder disease</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>1</StatusSortCode><Action id="7293">Synergist</Action><Company id="30151">Dynogen Pharmaceuticals Inc</Company><Country id="US">US</Country><Drug id="39897">Bicifadine</Drug><ParentCompany id="30151">Dynogen Pharmaceuticals Inc</ParentCompany><Status id="PRI">First Priority</Status><TherapyArea id="366">Genitourinary disease</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship>New use</DrugRelationship><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Patent id="PA3068301">WO-2005117872</Patent></Row><Row><Indication id="148">Headache</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>2</StatusSortCode><Action id="2946">Analgesic</Action><Company id="1052448">Euthymics Bioscience Inc</Company><Country id="WO">World</Country><Drug id="39897">Bicifadine</Drug><ParentCompany id="1052448">Euthymics Bioscience Inc</ParentCompany><Status id="PUB">First Publication</Status><TherapyArea id="677">Neurological disease</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship>New use</DrugRelationship><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Patent id="PA3195229">WO-2006050520</Patent></Row><Row><Indication id="443">Hyperthermia</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>2</StatusSortCode><Action id="2946">Analgesic</Action><Company id="1052448">Euthymics Bioscience Inc</Company><Country id="WO">World</Country><Drug id="39897">Bicifadine</Drug><ParentCompany id="1052448">Euthymics Bioscience Inc</ParentCompany><Status id="PUB">First Publication</Status><TherapyArea id="1023">Temperature disorder</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship>New use</DrugRelationship><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Patent id="PA3195229">WO-2006050520</Patent></Row><Row><Indication id="93">Depression</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>2</StatusSortCode><Action id="2946">Analgesic</Action><Company id="1052448">Euthymics Bioscience Inc</Company><Country id="WO">World</Country><Drug id="39897">Bicifadine</Drug><ParentCompany id="1052448">Euthymics Bioscience Inc</ParentCompany><Status id="PUB">First Publication</Status><TherapyArea id="207">Psychiatric disorder</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship>New use</DrugRelationship><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Patent id="PA3195229">WO-2006050520</Patent></Row><Row><Indication id="148">Headache</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>1</StatusSortCode><Action id="2946">Analgesic</Action><Company id="1052448">Euthymics Bioscience Inc</Company><Country id="US">US</Country><Drug id="39897">Bicifadine</Drug><ParentCompany id="1052448">Euthymics Bioscience Inc</ParentCompany><Status id="PRI">First Priority</Status><TherapyArea id="677">Neurological disease</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship>New use</DrugRelationship><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Patent id="PA3195229">WO-2006050520</Patent></Row><Row><Indication id="443">Hyperthermia</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>1</StatusSortCode><Action id="2946">Analgesic</Action><Company id="1052448">Euthymics Bioscience Inc</Company><Country id="US">US</Country><Drug id="39897">Bicifadine</Drug><ParentCompany id="1052448">Euthymics Bioscience Inc</ParentCompany><Status id="PRI">First Priority</Status><TherapyArea id="1023">Temperature disorder</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship>New use</DrugRelationship><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Patent id="PA3195229">WO-2006050520</Patent></Row><Row><Indication id="93">Depression</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>1</StatusSortCode><Action id="2946">Analgesic</Action><Company id="1052448">Euthymics Bioscience Inc</Company><Country id="US">US</Country><Drug id="39897">Bicifadine</Drug><ParentCompany id="1052448">Euthymics Bioscience Inc</ParentCompany><Status id="PRI">First Priority</Status><TherapyArea id="207">Psychiatric disorder</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship>New use</DrugRelationship><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Patent id="PA3195229">WO-2006050520</Patent></Row><Row><Indication id="187">Urinary incontinence</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>2</StatusSortCode><Action id="285">Norepinephrine uptake inhibitor</Action><Company id="1052448">Euthymics Bioscience Inc</Company><Country id="WO">World</Country><Drug id="39897">bicifadine (sustained-release, pain), DOV</Drug><ParentCompany id="1052448">Euthymics Bioscience Inc</ParentCompany><Status id="PUB">First Publication</Status><TherapyArea id="366">Genitourinary disease</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship>New use</DrugRelationship><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Patent id="PA3235458">WO-2006102029</Patent></Row><Row><Indication id="483">Urinary dysfunction</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>2</StatusSortCode><Action id="285">Norepinephrine uptake inhibitor</Action><Company id="1052448">Euthymics Bioscience Inc</Company><Country id="WO">World</Country><Drug id="39897">bicifadine (sustained-release, pain), DOV</Drug><ParentCompany id="1052448">Euthymics Bioscience Inc</ParentCompany><Status id="PUB">First Publication</Status><TherapyArea id="366">Genitourinary disease</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship>New use</DrugRelationship><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Patent id="PA3235458">WO-2006102029</Patent></Row><Row><Indication id="187">Urinary incontinence</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>2</StatusSortCode><Action id="3">5-HT uptake inhibitor</Action><Company id="1052448">Euthymics Bioscience Inc</Company><Country id="WO">World</Country><Drug id="39897">bicifadine (sustained-release, pain), DOV</Drug><ParentCompany id="1052448">Euthymics Bioscience Inc</ParentCompany><Status id="PUB">First Publication</Status><TherapyArea id="366">Genitourinary disease</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship>New use</DrugRelationship><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Patent id="PA3235458">WO-2006102029</Patent></Row><Row><Indication id="483">Urinary dysfunction</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>2</StatusSortCode><Action id="3">5-HT uptake inhibitor</Action><Company id="1052448">Euthymics Bioscience Inc</Company><Country id="WO">World</Country><Drug id="39897">bicifadine (sustained-release, pain), DOV</Drug><ParentCompany id="1052448">Euthymics Bioscience Inc</ParentCompany><Status id="PUB">First Publication</Status><TherapyArea id="366">Genitourinary disease</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship>New use</DrugRelationship><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Patent id="PA3235458">WO-2006102029</Patent></Row><Row><Indication id="187">Urinary incontinence</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>2</StatusSortCode><Action id="285">Norepinephrine uptake inhibitor</Action><Company id="1052448">Euthymics Bioscience Inc</Company><Country id="WO">World</Country><Drug id="39897">bicifadine (sustained-release, pain), DOV</Drug><ParentCompany id="1052448">Euthymics Bioscience Inc</ParentCompany><Status id="PUB">First Publication</Status><TherapyArea id="366">Genitourinary disease</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship>Formulation</DrugRelationship><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Patent id="PA3235458">WO-2006102029</Patent></Row><Row><Indication id="483">Urinary dysfunction</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>2</StatusSortCode><Action id="285">Norepinephrine uptake inhibitor</Action><Company id="1052448">Euthymics Bioscience Inc</Company><Country id="WO">World</Country><Drug id="39897">bicifadine (sustained-release, pain), DOV</Drug><ParentCompany id="1052448">Euthymics Bioscience Inc</ParentCompany><Status id="PUB">First Publication</Status><TherapyArea id="366">Genitourinary disease</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship>Formulation</DrugRelationship><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Patent id="PA3235458">WO-2006102029</Patent></Row><Row><Indication id="187">Urinary incontinence</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>2</StatusSortCode><Action id="3">5-HT uptake inhibitor</Action><Company id="1052448">Euthymics Bioscience Inc</Company><Country id="WO">World</Country><Drug id="39897">bicifadine (sustained-release, pain), DOV</Drug><ParentCompany id="1052448">Euthymics Bioscience Inc</ParentCompany><Status id="PUB">First Publication</Status><TherapyArea id="366">Genitourinary disease</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship>Formulation</DrugRelationship><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Patent id="PA3235458">WO-2006102029</Patent></Row><Row><Indication id="483">Urinary dysfunction</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>2</StatusSortCode><Action id="3">5-HT uptake inhibitor</Action><Company id="1052448">Euthymics Bioscience Inc</Company><Country id="WO">World</Country><Drug id="39897">bicifadine (sustained-release, pain), DOV</Drug><ParentCompany id="1052448">Euthymics Bioscience Inc</ParentCompany><Status id="PUB">First Publication</Status><TherapyArea id="366">Genitourinary disease</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship>Formulation</DrugRelationship><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Patent id="PA3235458">WO-2006102029</Patent></Row><Row><Indication id="187">Urinary incontinence</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>1</StatusSortCode><Action id="285">Norepinephrine uptake inhibitor</Action><Company id="1052448">Euthymics Bioscience Inc</Company><Country id="US">US</Country><Drug id="39897">bicifadine (sustained-release, pain), DOV</Drug><ParentCompany id="1052448">Euthymics Bioscience Inc</ParentCompany><Status id="PRI">First Priority</Status><TherapyArea id="366">Genitourinary disease</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship>New use</DrugRelationship><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Patent id="PA3235458">WO-2006102029</Patent></Row><Row><Indication id="483">Urinary dysfunction</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>1</StatusSortCode><Action id="285">Norepinephrine uptake inhibitor</Action><Company id="1052448">Euthymics Bioscience Inc</Company><Country id="US">US</Country><Drug id="39897">bicifadine (sustained-release, pain), DOV</Drug><ParentCompany id="1052448">Euthymics Bioscience Inc</ParentCompany><Status id="PRI">First Priority</Status><TherapyArea id="366">Genitourinary disease</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship>New use</DrugRelationship><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Patent id="PA3235458">WO-2006102029</Patent></Row><Row><Indication id="187">Urinary incontinence</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>1</StatusSortCode><Action id="3">5-HT uptake inhibitor</Action><Company id="1052448">Euthymics Bioscience Inc</Company><Country id="US">US</Country><Drug id="39897">bicifadine (sustained-release, pain), DOV</Drug><ParentCompany id="1052448">Euthymics Bioscience Inc</ParentCompany><Status id="PRI">First Priority</Status><TherapyArea id="366">Genitourinary disease</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship>New use</DrugRelationship><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Patent id="PA3235458">WO-2006102029</Patent></Row><Row><Indication id="483">Urinary dysfunction</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>1</StatusSortCode><Action id="3">5-HT uptake inhibitor</Action><Company id="1052448">Euthymics Bioscience Inc</Company><Country id="US">US</Country><Drug id="39897">bicifadine (sustained-release, pain), DOV</Drug><ParentCompany id="1052448">Euthymics Bioscience Inc</ParentCompany><Status id="PRI">First Priority</Status><TherapyArea id="366">Genitourinary disease</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship>New use</DrugRelationship><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Patent id="PA3235458">WO-2006102029</Patent></Row><Row><Indication id="187">Urinary incontinence</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>1</StatusSortCode><Action id="285">Norepinephrine uptake inhibitor</Action><Company id="1052448">Euthymics Bioscience Inc</Company><Country id="US">US</Country><Drug id="39897">bicifadine (sustained-release, pain), DOV</Drug><ParentCompany id="1052448">Euthymics Bioscience Inc</ParentCompany><Status id="PRI">First Priority</Status><TherapyArea id="366">Genitourinary disease</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship>Formulation</DrugRelationship><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Patent id="PA3235458">WO-2006102029</Patent></Row><Row><Indication id="483">Urinary dysfunction</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>1</StatusSortCode><Action id="285">Norepinephrine uptake inhibitor</Action><Company id="1052448">Euthymics Bioscience Inc</Company><Country id="US">US</Country><Drug id="39897">bicifadine (sustained-release, pain), DOV</Drug><ParentCompany id="1052448">Euthymics Bioscience Inc</ParentCompany><Status id="PRI">First Priority</Status><TherapyArea id="366">Genitourinary disease</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship>Formulation</DrugRelationship><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Patent id="PA3235458">WO-2006102029</Patent></Row><Row><Indication id="187">Urinary incontinence</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>1</StatusSortCode><Action id="3">5-HT uptake inhibitor</Action><Company id="1052448">Euthymics Bioscience Inc</Company><Country id="US">US</Country><Drug id="39897">bicifadine (sustained-release, pain), DOV</Drug><ParentCompany id="1052448">Euthymics Bioscience Inc</ParentCompany><Status id="PRI">First Priority</Status><TherapyArea id="366">Genitourinary disease</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship>Formulation</DrugRelationship><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Patent id="PA3235458">WO-2006102029</Patent></Row><Row><Indication id="483">Urinary dysfunction</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>1</StatusSortCode><Action id="3">5-HT uptake inhibitor</Action><Company id="1052448">Euthymics Bioscience Inc</Company><Country id="US">US</Country><Drug id="39897">bicifadine (sustained-release, pain), DOV</Drug><ParentCompany id="1052448">Euthymics Bioscience Inc</ParentCompany><Status id="PRI">First Priority</Status><TherapyArea id="366">Genitourinary disease</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship>Formulation</DrugRelationship><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Patent id="PA3235458">WO-2006102029</Patent></Row><Row><Indication id="1295">Neuropathic pain</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>2</StatusSortCode><Action id="285">Norepinephrine uptake inhibitor</Action><Company id="1052448">Euthymics Bioscience Inc</Company><Country id="WO">World</Country><Drug id="39897">bicifadine (sustained-release, pain), DOV</Drug><ParentCompany id="1052448">Euthymics Bioscience Inc</ParentCompany><Status id="PUB">First Publication</Status><TherapyArea id="677">Neurological disease</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship>New use</DrugRelationship><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Patent id="PA3460606">WO-2007014264</Patent></Row><Row><Indication id="1295">Neuropathic pain</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>2</StatusSortCode><Action id="3">5-HT uptake inhibitor</Action><Company id="1052448">Euthymics Bioscience Inc</Company><Country id="WO">World</Country><Drug id="39897">bicifadine (sustained-release, pain), DOV</Drug><ParentCompany id="1052448">Euthymics Bioscience Inc</ParentCompany><Status id="PUB">First Publication</Status><TherapyArea id="677">Neurological disease</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship>New use</DrugRelationship><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Patent id="PA3460606">WO-2007014264</Patent></Row><Row><Indication id="1295">Neuropathic pain</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>1</StatusSortCode><Action id="285">Norepinephrine uptake inhibitor</Action><Company id="1052448">Euthymics Bioscience Inc</Company><Country id="US">US</Country><Drug id="39897">bicifadine (sustained-release, pain), DOV</Drug><ParentCompany id="1052448">Euthymics Bioscience Inc</ParentCompany><Status id="PRI">First Priority</Status><TherapyArea id="677">Neurological disease</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship>New use</DrugRelationship><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Patent id="PA3460606">WO-2007014264</Patent></Row><Row><Indication id="1295">Neuropathic pain</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>1</StatusSortCode><Action id="3">5-HT uptake inhibitor</Action><Company id="1052448">Euthymics Bioscience Inc</Company><Country id="US">US</Country><Drug id="39897">bicifadine (sustained-release, pain), DOV</Drug><ParentCompany id="1052448">Euthymics Bioscience Inc</ParentCompany><Status id="PRI">First Priority</Status><TherapyArea id="677">Neurological disease</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship>New use</DrugRelationship><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Patent id="PA3460606">WO-2007014264</Patent></Row><Row><Indication id="106">Eating disorder</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>2</StatusSortCode><Action id="151">Dopamine uptake inhibitor</Action><Company id="18077">Merck &amp; Co Inc</Company><Country id="WO">World</Country><Drug id="39897">Bicifadine</Drug><ParentCompany id="18077">Merck &amp; Co Inc</ParentCompany><Status id="PUB">First Publication</Status><TherapyArea id="207">Psychiatric disorder</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship>Process</DrugRelationship><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Patent id="PA3566056">WO-2007127421</Patent></Row><Row><Indication id="187">Urinary incontinence</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>2</StatusSortCode><Action id="151">Dopamine uptake inhibitor</Action><Company id="18077">Merck &amp; Co Inc</Company><Country id="WO">World</Country><Drug id="39897">Bicifadine</Drug><ParentCompany id="18077">Merck &amp; Co Inc</ParentCompany><Status id="PUB">First Publication</Status><TherapyArea id="366">Genitourinary disease</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship>Process</DrugRelationship><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Patent id="PA3566056">WO-2007127421</Patent></Row><Row><Indication id="238">Obesity</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>2</StatusSortCode><Action id="151">Dopamine uptake inhibitor</Action><Company id="18077">Merck &amp; Co Inc</Company><Country id="WO">World</Country><Drug id="39897">Bicifadine</Drug><ParentCompany id="18077">Merck &amp; Co Inc</ParentCompany><Status id="PUB">First Publication</Status><TherapyArea id="684">Nutritional disorder</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship>Process</DrugRelationship><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Patent id="PA3566056">WO-2007127421</Patent></Row><Row><Indication id="25">Anxiety disorder</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>2</StatusSortCode><Action id="151">Dopamine uptake inhibitor</Action><Company id="18077">Merck &amp; Co Inc</Company><Country id="WO">World</Country><Drug id="39897">Bicifadine</Drug><ParentCompany id="18077">Merck &amp; Co Inc</ParentCompany><Status id="PUB">First Publication</Status><TherapyArea id="207">Psychiatric disorder</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship>Process</DrugRelationship><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Patent id="PA3566056">WO-2007127421</Patent></Row><Row><Indication id="93">Depression</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>2</StatusSortCode><Action id="151">Dopamine uptake inhibitor</Action><Company id="18077">Merck &amp; Co Inc</Company><Country id="WO">World</Country><Drug id="39897">Bicifadine</Drug><ParentCompany id="18077">Merck &amp; Co Inc</ParentCompany><Status id="PUB">First Publication</Status><TherapyArea id="207">Psychiatric disorder</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship>Process</DrugRelationship><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Patent id="PA3566056">WO-2007127421</Patent></Row><Row><Indication id="106">Eating disorder</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>2</StatusSortCode><Action id="285">Norepinephrine uptake inhibitor</Action><Company id="18077">Merck &amp; Co Inc</Company><Country id="WO">World</Country><Drug id="39897">Bicifadine</Drug><ParentCompany id="18077">Merck &amp; Co Inc</ParentCompany><Status id="PUB">First Publication</Status><TherapyArea id="207">Psychiatric disorder</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship>Process</DrugRelationship><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Patent id="PA3566056">WO-2007127421</Patent></Row><Row><Indication id="187">Urinary incontinence</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>2</StatusSortCode><Action id="285">Norepinephrine uptake inhibitor</Action><Company id="18077">Merck &amp; Co Inc</Company><Country id="WO">World</Country><Drug id="39897">Bicifadine</Drug><ParentCompany id="18077">Merck &amp; Co Inc</ParentCompany><Status id="PUB">First Publication</Status><TherapyArea id="366">Genitourinary disease</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship>Process</DrugRelationship><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Patent id="PA3566056">WO-2007127421</Patent></Row><Row><Indication id="238">Obesity</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>2</StatusSortCode><Action id="285">Norepinephrine uptake inhibitor</Action><Company id="18077">Merck &amp; Co Inc</Company><Country id="WO">World</Country><Drug id="39897">Bicifadine</Drug><ParentCompany id="18077">Merck &amp; Co Inc</ParentCompany><Status id="PUB">First Publication</Status><TherapyArea id="684">Nutritional disorder</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship>Process</DrugRelationship><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Patent id="PA3566056">WO-2007127421</Patent></Row><Row><Indication id="25">Anxiety disorder</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>2</StatusSortCode><Action id="285">Norepinephrine uptake inhibitor</Action><Company id="18077">Merck &amp; Co Inc</Company><Country id="WO">World</Country><Drug id="39897">Bicifadine</Drug><ParentCompany id="18077">Merck &amp; Co Inc</ParentCompany><Status id="PUB">First Publication</Status><TherapyArea id="207">Psychiatric disorder</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship>Process</DrugRelationship><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Patent id="PA3566056">WO-2007127421</Patent></Row><Row><Indication id="93">Depression</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>2</StatusSortCode><Action id="285">Norepinephrine uptake inhibitor</Action><Company id="18077">Merck &amp; Co Inc</Company><Country id="WO">World</Country><Drug id="39897">Bicifadine</Drug><ParentCompany id="18077">Merck &amp; Co Inc</ParentCompany><Status id="PUB">First Publication</Status><TherapyArea id="207">Psychiatric disorder</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship>Process</DrugRelationship><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Patent id="PA3566056">WO-2007127421</Patent></Row><Row><Indication id="106">Eating disorder</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>2</StatusSortCode><Action id="3">5-HT uptake inhibitor</Action><Company id="18077">Merck &amp; Co Inc</Company><Country id="WO">World</Country><Drug id="39897">Bicifadine</Drug><ParentCompany id="18077">Merck &amp; Co Inc</ParentCompany><Status id="PUB">First Publication</Status><TherapyArea id="207">Psychiatric disorder</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship>Process</DrugRelationship><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Patent id="PA3566056">WO-2007127421</Patent></Row><Row><Indication id="187">Urinary incontinence</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>2</StatusSortCode><Action id="3">5-HT uptake inhibitor</Action><Company id="18077">Merck &amp; Co Inc</Company><Country id="WO">World</Country><Drug id="39897">Bicifadine</Drug><ParentCompany id="18077">Merck &amp; Co Inc</ParentCompany><Status id="PUB">First Publication</Status><TherapyArea id="366">Genitourinary disease</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship>Process</DrugRelationship><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Patent id="PA3566056">WO-2007127421</Patent></Row><Row><Indication id="238">Obesity</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>2</StatusSortCode><Action id="3">5-HT uptake inhibitor</Action><Company id="18077">Merck &amp; Co Inc</Company><Country id="WO">World</Country><Drug id="39897">Bicifadine</Drug><ParentCompany id="18077">Merck &amp; Co Inc</ParentCompany><Status id="PUB">First Publication</Status><TherapyArea id="684">Nutritional disorder</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship>Process</DrugRelationship><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Patent id="PA3566056">WO-2007127421</Patent></Row><Row><Indication id="25">Anxiety disorder</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>2</StatusSortCode><Action id="3">5-HT uptake inhibitor</Action><Company id="18077">Merck &amp; Co Inc</Company><Country id="WO">World</Country><Drug id="39897">Bicifadine</Drug><ParentCompany id="18077">Merck &amp; Co Inc</ParentCompany><Status id="PUB">First Publication</Status><TherapyArea id="207">Psychiatric disorder</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship>Process</DrugRelationship><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Patent id="PA3566056">WO-2007127421</Patent></Row><Row><Indication id="93">Depression</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>2</StatusSortCode><Action id="3">5-HT uptake inhibitor</Action><Company id="18077">Merck &amp; Co Inc</Company><Country id="WO">World</Country><Drug id="39897">Bicifadine</Drug><ParentCompany id="18077">Merck &amp; Co Inc</ParentCompany><Status id="PUB">First Publication</Status><TherapyArea id="207">Psychiatric disorder</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship>Process</DrugRelationship><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Patent id="PA3566056">WO-2007127421</Patent></Row><Row><Indication id="106">Eating disorder</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>1</StatusSortCode><Action id="151">Dopamine uptake inhibitor</Action><Company id="18077">Merck &amp; Co Inc</Company><Country id="US">US</Country><Drug id="39897">Bicifadine</Drug><ParentCompany id="18077">Merck &amp; Co Inc</ParentCompany><Status id="PRI">First Priority</Status><TherapyArea id="207">Psychiatric disorder</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship>Process</DrugRelationship><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Patent id="PA3566056">WO-2007127421</Patent></Row><Row><Indication id="187">Urinary incontinence</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>1</StatusSortCode><Action id="151">Dopamine uptake inhibitor</Action><Company id="18077">Merck &amp; Co Inc</Company><Country id="US">US</Country><Drug id="39897">Bicifadine</Drug><ParentCompany id="18077">Merck &amp; Co Inc</ParentCompany><Status id="PRI">First Priority</Status><TherapyArea id="366">Genitourinary disease</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship>Process</DrugRelationship><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Patent id="PA3566056">WO-2007127421</Patent></Row><Row><Indication id="238">Obesity</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>1</StatusSortCode><Action id="151">Dopamine uptake inhibitor</Action><Company id="18077">Merck &amp; Co Inc</Company><Country id="US">US</Country><Drug id="39897">Bicifadine</Drug><ParentCompany id="18077">Merck &amp; Co Inc</ParentCompany><Status id="PRI">First Priority</Status><TherapyArea id="684">Nutritional disorder</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship>Process</DrugRelationship><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Patent id="PA3566056">WO-2007127421</Patent></Row><Row><Indication id="25">Anxiety disorder</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>1</StatusSortCode><Action id="151">Dopamine uptake inhibitor</Action><Company id="18077">Merck &amp; Co Inc</Company><Country id="US">US</Country><Drug id="39897">Bicifadine</Drug><ParentCompany id="18077">Merck &amp; Co Inc</ParentCompany><Status id="PRI">First Priority</Status><TherapyArea id="207">Psychiatric disorder</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship>Process</DrugRelationship><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Patent id="PA3566056">WO-2007127421</Patent></Row><Row><Indication id="93">Depression</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>1</StatusSortCode><Action id="151">Dopamine uptake inhibitor</Action><Company id="18077">Merck &amp; Co Inc</Company><Country id="US">US</Country><Drug id="39897">Bicifadine</Drug><ParentCompany id="18077">Merck &amp; Co Inc</ParentCompany><Status id="PRI">First Priority</Status><TherapyArea id="207">Psychiatric disorder</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship>Process</DrugRelationship><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Patent id="PA3566056">WO-2007127421</Patent></Row><Row><Indication id="106">Eating disorder</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>1</StatusSortCode><Action id="285">Norepinephrine uptake inhibitor</Action><Company id="18077">Merck &amp; Co Inc</Company><Country id="US">US</Country><Drug id="39897">Bicifadine</Drug><ParentCompany id="18077">Merck &amp; Co Inc</ParentCompany><Status id="PRI">First Priority</Status><TherapyArea id="207">Psychiatric disorder</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship>Process</DrugRelationship><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Patent id="PA3566056">WO-2007127421</Patent></Row><Row><Indication id="187">Urinary incontinence</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>1</StatusSortCode><Action id="285">Norepinephrine uptake inhibitor</Action><Company id="18077">Merck &amp; Co Inc</Company><Country id="US">US</Country><Drug id="39897">Bicifadine</Drug><ParentCompany id="18077">Merck &amp; Co Inc</ParentCompany><Status id="PRI">First Priority</Status><TherapyArea id="366">Genitourinary disease</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship>Process</DrugRelationship><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Patent id="PA3566056">WO-2007127421</Patent></Row><Row><Indication id="238">Obesity</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>1</StatusSortCode><Action id="285">Norepinephrine uptake inhibitor</Action><Company id="18077">Merck &amp; Co Inc</Company><Country id="US">US</Country><Drug id="39897">Bicifadine</Drug><ParentCompany id="18077">Merck &amp; Co Inc</ParentCompany><Status id="PRI">First Priority</Status><TherapyArea id="684">Nutritional disorder</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship>Process</DrugRelationship><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Patent id="PA3566056">WO-2007127421</Patent></Row><Row><Indication id="25">Anxiety disorder</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>1</StatusSortCode><Action id="285">Norepinephrine uptake inhibitor</Action><Company id="18077">Merck &amp; Co Inc</Company><Country id="US">US</Country><Drug id="39897">Bicifadine</Drug><ParentCompany id="18077">Merck &amp; Co Inc</ParentCompany><Status id="PRI">First Priority</Status><TherapyArea id="207">Psychiatric disorder</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship>Process</DrugRelationship><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Patent id="PA3566056">WO-2007127421</Patent></Row><Row><Indication id="93">Depression</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>1</StatusSortCode><Action id="285">Norepinephrine uptake inhibitor</Action><Company id="18077">Merck &amp; Co Inc</Company><Country id="US">US</Country><Drug id="39897">Bicifadine</Drug><ParentCompany id="18077">Merck &amp; Co Inc</ParentCompany><Status id="PRI">First Priority</Status><TherapyArea id="207">Psychiatric disorder</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship>Process</DrugRelationship><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Patent id="PA3566056">WO-2007127421</Patent></Row><Row><Indication id="106">Eating disorder</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>1</StatusSortCode><Action id="3">5-HT uptake inhibitor</Action><Company id="18077">Merck &amp; Co Inc</Company><Country id="US">US</Country><Drug id="39897">Bicifadine</Drug><ParentCompany id="18077">Merck &amp; Co Inc</ParentCompany><Status id="PRI">First Priority</Status><TherapyArea id="207">Psychiatric disorder</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship>Process</DrugRelationship><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Patent id="PA3566056">WO-2007127421</Patent></Row><Row><Indication id="187">Urinary incontinence</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>1</StatusSortCode><Action id="3">5-HT uptake inhibitor</Action><Company id="18077">Merck &amp; Co Inc</Company><Country id="US">US</Country><Drug id="39897">Bicifadine</Drug><ParentCompany id="18077">Merck &amp; Co Inc</ParentCompany><Status id="PRI">First Priority</Status><TherapyArea id="366">Genitourinary disease</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship>Process</DrugRelationship><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Patent id="PA3566056">WO-2007127421</Patent></Row><Row><Indication id="238">Obesity</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>1</StatusSortCode><Action id="3">5-HT uptake inhibitor</Action><Company id="18077">Merck &amp; Co Inc</Company><Country id="US">US</Country><Drug id="39897">Bicifadine</Drug><ParentCompany id="18077">Merck &amp; Co Inc</ParentCompany><Status id="PRI">First Priority</Status><TherapyArea id="684">Nutritional disorder</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship>Process</DrugRelationship><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Patent id="PA3566056">WO-2007127421</Patent></Row><Row><Indication id="25">Anxiety disorder</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>1</StatusSortCode><Action id="3">5-HT uptake inhibitor</Action><Company id="18077">Merck &amp; Co Inc</Company><Country id="US">US</Country><Drug id="39897">Bicifadine</Drug><ParentCompany id="18077">Merck &amp; Co Inc</ParentCompany><Status id="PRI">First Priority</Status><TherapyArea id="207">Psychiatric disorder</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship>Process</DrugRelationship><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Patent id="PA3566056">WO-2007127421</Patent></Row><Row><Indication id="93">Depression</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>1</StatusSortCode><Action id="3">5-HT uptake inhibitor</Action><Company id="18077">Merck &amp; Co Inc</Company><Country id="US">US</Country><Drug id="39897">Bicifadine</Drug><ParentCompany id="18077">Merck &amp; Co Inc</ParentCompany><Status id="PRI">First Priority</Status><TherapyArea id="207">Psychiatric disorder</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship>Process</DrugRelationship><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Patent id="PA3566056">WO-2007127421</Patent></Row><Row><Indication id="188">Inflammatory disease</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>2</StatusSortCode><Action id="285">Norepinephrine uptake inhibitor</Action><Company id="1052448">Euthymics Bioscience Inc</Company><Country id="WO">World</Country><Drug id="39897">bicifadine (sustained-release, pain), DOV</Drug><ParentCompany id="1052448">Euthymics Bioscience Inc</ParentCompany><Status id="PUB">First Publication</Status><TherapyArea id="188">Inflammatory disease</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship>Component of Combination</DrugRelationship><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Patent id="PA3592729">WO-2008008474</Patent></Row><Row><Indication id="20">Pain</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>2</StatusSortCode><Action id="285">Norepinephrine uptake inhibitor</Action><Company id="1052448">Euthymics Bioscience Inc</Company><Country id="WO">World</Country><Drug id="39897">bicifadine (sustained-release, pain), DOV</Drug><ParentCompany id="1052448">Euthymics Bioscience Inc</ParentCompany><Status id="PUB">First Publication</Status><TherapyArea id="677">Neurological disease</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship>Component of Combination</DrugRelationship><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Patent id="PA3592729">WO-2008008474</Patent></Row><Row><Indication id="245">Osteoarthritis</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>2</StatusSortCode><Action id="285">Norepinephrine uptake inhibitor</Action><Company id="1052448">Euthymics Bioscience Inc</Company><Country id="WO">World</Country><Drug id="39897">bicifadine (sustained-release, pain), DOV</Drug><ParentCompany id="1052448">Euthymics Bioscience Inc</ParentCompany><Status id="PUB">First Publication</Status><TherapyArea id="188">Inflammatory disease</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship>Component of Combination</DrugRelationship><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Patent id="PA3592729">WO-2008008474</Patent></Row><Row><Indication id="188">Inflammatory disease</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>2</StatusSortCode><Action id="2955">Non-steroidal anti-inflammatory</Action><Company id="1052448">Euthymics Bioscience Inc</Company><Country id="WO">World</Country><Drug id="39897">bicifadine (sustained-release, pain), DOV</Drug><ParentCompany id="1052448">Euthymics Bioscience Inc</ParentCompany><Status id="PUB">First Publication</Status><TherapyArea id="188">Inflammatory disease</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship>Component of Combination</DrugRelationship><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Patent id="PA3592729">WO-2008008474</Patent></Row><Row><Indication id="20">Pain</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>2</StatusSortCode><Action id="2955">Non-steroidal anti-inflammatory</Action><Company id="1052448">Euthymics Bioscience Inc</Company><Country id="WO">World</Country><Drug id="39897">bicifadine (sustained-release, pain), DOV</Drug><ParentCompany id="1052448">Euthymics Bioscience Inc</ParentCompany><Status id="PUB">First Publication</Status><TherapyArea id="677">Neurological disease</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship>Component of Combination</DrugRelationship><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Patent id="PA3592729">WO-2008008474</Patent></Row><Row><Indication id="245">Osteoarthritis</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>2</StatusSortCode><Action id="2955">Non-steroidal anti-inflammatory</Action><Company id="1052448">Euthymics Bioscience Inc</Company><Country id="WO">World</Country><Drug id="39897">bicifadine (sustained-release, pain), DOV</Drug><ParentCompany id="1052448">Euthymics Bioscience Inc</ParentCompany><Status id="PUB">First Publication</Status><TherapyArea id="188">Inflammatory disease</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship>Component of Combination</DrugRelationship><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Patent id="PA3592729">WO-2008008474</Patent></Row><Row><Indication id="188">Inflammatory disease</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>2</StatusSortCode><Action id="3">5-HT uptake inhibitor</Action><Company id="1052448">Euthymics Bioscience Inc</Company><Country id="WO">World</Country><Drug id="39897">bicifadine (sustained-release, pain), DOV</Drug><ParentCompany id="1052448">Euthymics Bioscience Inc</ParentCompany><Status id="PUB">First Publication</Status><TherapyArea id="188">Inflammatory disease</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship>Component of Combination</DrugRelationship><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Patent id="PA3592729">WO-2008008474</Patent></Row><Row><Indication id="20">Pain</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>2</StatusSortCode><Action id="3">5-HT uptake inhibitor</Action><Company id="1052448">Euthymics Bioscience Inc</Company><Country id="WO">World</Country><Drug id="39897">bicifadine (sustained-release, pain), DOV</Drug><ParentCompany id="1052448">Euthymics Bioscience Inc</ParentCompany><Status id="PUB">First Publication</Status><TherapyArea id="677">Neurological disease</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship>Component of Combination</DrugRelationship><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Patent id="PA3592729">WO-2008008474</Patent></Row><Row><Indication id="245">Osteoarthritis</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>2</StatusSortCode><Action id="3">5-HT uptake inhibitor</Action><Company id="1052448">Euthymics Bioscience Inc</Company><Country id="WO">World</Country><Drug id="39897">bicifadine (sustained-release, pain), DOV</Drug><ParentCompany id="1052448">Euthymics Bioscience Inc</ParentCompany><Status id="PUB">First Publication</Status><TherapyArea id="188">Inflammatory disease</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship>Component of Combination</DrugRelationship><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Patent id="PA3592729">WO-2008008474</Patent></Row><Row><Indication id="188">Inflammatory disease</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>1</StatusSortCode><Action id="285">Norepinephrine uptake inhibitor</Action><Company id="1052448">Euthymics Bioscience Inc</Company><Country id="US">US</Country><Drug id="39897">bicifadine (sustained-release, pain), DOV</Drug><ParentCompany id="1052448">Euthymics Bioscience Inc</ParentCompany><Status id="PRI">First Priority</Status><TherapyArea id="188">Inflammatory disease</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship>Component of Combination</DrugRelationship><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Patent id="PA3592729">WO-2008008474</Patent></Row><Row><Indication id="20">Pain</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>1</StatusSortCode><Action id="285">Norepinephrine uptake inhibitor</Action><Company id="1052448">Euthymics Bioscience Inc</Company><Country id="US">US</Country><Drug id="39897">bicifadine (sustained-release, pain), DOV</Drug><ParentCompany id="1052448">Euthymics Bioscience Inc</ParentCompany><Status id="PRI">First Priority</Status><TherapyArea id="677">Neurological disease</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship>Component of Combination</DrugRelationship><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Patent id="PA3592729">WO-2008008474</Patent></Row><Row><Indication id="245">Osteoarthritis</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>1</StatusSortCode><Action id="285">Norepinephrine uptake inhibitor</Action><Company id="1052448">Euthymics Bioscience Inc</Company><Country id="US">US</Country><Drug id="39897">bicifadine (sustained-release, pain), DOV</Drug><ParentCompany id="1052448">Euthymics Bioscience Inc</ParentCompany><Status id="PRI">First Priority</Status><TherapyArea id="188">Inflammatory disease</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship>Component of Combination</DrugRelationship><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Patent id="PA3592729">WO-2008008474</Patent></Row><Row><Indication id="188">Inflammatory disease</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>1</StatusSortCode><Action id="2955">Non-steroidal anti-inflammatory</Action><Company id="1052448">Euthymics Bioscience Inc</Company><Country id="US">US</Country><Drug id="39897">bicifadine (sustained-release, pain), DOV</Drug><ParentCompany id="1052448">Euthymics Bioscience Inc</ParentCompany><Status id="PRI">First Priority</Status><TherapyArea id="188">Inflammatory disease</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship>Component of Combination</DrugRelationship><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Patent id="PA3592729">WO-2008008474</Patent></Row><Row><Indication id="20">Pain</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>1</StatusSortCode><Action id="2955">Non-steroidal anti-inflammatory</Action><Company id="1052448">Euthymics Bioscience Inc</Company><Country id="US">US</Country><Drug id="39897">bicifadine (sustained-release, pain), DOV</Drug><ParentCompany id="1052448">Euthymics Bioscience Inc</ParentCompany><Status id="PRI">First Priority</Status><TherapyArea id="677">Neurological disease</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship>Component of Combination</DrugRelationship><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Patent id="PA3592729">WO-2008008474</Patent></Row><Row><Indication id="245">Osteoarthritis</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>1</StatusSortCode><Action id="2955">Non-steroidal anti-inflammatory</Action><Company id="1052448">Euthymics Bioscience Inc</Company><Country id="US">US</Country><Drug id="39897">bicifadine (sustained-release, pain), DOV</Drug><ParentCompany id="1052448">Euthymics Bioscience Inc</ParentCompany><Status id="PRI">First Priority</Status><TherapyArea id="188">Inflammatory disease</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship>Component of Combination</DrugRelationship><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Patent id="PA3592729">WO-2008008474</Patent></Row><Row><Indication id="188">Inflammatory disease</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>1</StatusSortCode><Action id="3">5-HT uptake inhibitor</Action><Company id="1052448">Euthymics Bioscience Inc</Company><Country id="US">US</Country><Drug id="39897">bicifadine (sustained-release, pain), DOV</Drug><ParentCompany id="1052448">Euthymics Bioscience Inc</ParentCompany><Status id="PRI">First Priority</Status><TherapyArea id="188">Inflammatory disease</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship>Component of Combination</DrugRelationship><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Patent id="PA3592729">WO-2008008474</Patent></Row><Row><Indication id="20">Pain</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>1</StatusSortCode><Action id="3">5-HT uptake inhibitor</Action><Company id="1052448">Euthymics Bioscience Inc</Company><Country id="US">US</Country><Drug id="39897">bicifadine (sustained-release, pain), DOV</Drug><ParentCompany id="1052448">Euthymics Bioscience Inc</ParentCompany><Status id="PRI">First Priority</Status><TherapyArea id="677">Neurological disease</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship>Component of Combination</DrugRelationship><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Patent id="PA3592729">WO-2008008474</Patent></Row><Row><Indication id="245">Osteoarthritis</Indication><AuthorityGroup></AuthorityGroup><EntityType></EntityType><StatusSortCode>1</StatusSortCode><Action id="3">5-HT uptake inhibitor</Action><Company id="1052448">Euthymics Bioscience Inc</Company><Country id="US">US</Country><Drug id="39897">bicifadine (sustained-release, pain), DOV</Drug><ParentCompany id="1052448">Euthymics Bioscience Inc</ParentCompany><Status id="PRI">First Priority</Status><TherapyArea id="188">Inflammatory disease</TherapyArea><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><DrugRelationship>Component of Combination</DrugRelationship><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Patent id="PA3592729">WO-2008008474</Patent></Row></ns2:com.thomsonreuters.ls.service.contract.analytics.v2.soap.AnalyticsOutputV2>